IP Library Granted Patent US 9,132,116
Granted Patent B2
US 9,132,116 · App. 12/510,750 · Granted Sep 15, 2015

Mast cell stabilizers to prevent or treat laminitis

Inventor: Charles F. Owen (Littleton, CO)
Assignee: WILLOWCROFT PHARM INC.
A61K31/352A61K31/436A61K31/519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,116
App. No.
12/510,750
Granted
Sep 15, 2015
Kind
B2
Abstract

Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.

Claims (16)

1. A method for the treatment of laminitis, the method comprising administering cromolyn sodium to a horse in need thereof, wherein the cromolyn sodium is administered through an intravenous injection in a dose of between about 0.5 and about 10 mg/kg of the horse's body weight and wherein the cromolyn sodium treats laminitis in the horse.

2. The method of claim 1 , wherein the horse suffers from acute laminitis and has one or more affected sites and wherein the cromolyn sodium is administered directly to each of the one or more affected sites.

3. The method of claim 1 , wherein the horse suffers from acute laminitis and wherein the cromolyn sodium is administered in a single dose.

4. The method of claim 1 , the method further comprising administering another intravenous dose of cromolyn sodium to the horse within about 3 to 4 days after administering a first dose.

5. A method for the treatment of laminitis, the method comprising administering nedocromil sodium to a horse in need thereof, wherein the nedocromil sodium is administered through an intravenous injection in a dose of between about 0.5 and 10 mg/kg of the horse's body weight and wherein the nedocromil treats laminitis in the horse.

6. The method of claim 5 , wherein the horse suffers from acute laminitis and has one or more affected sites and wherein the nedocromil sodium is administered directly to the each of the one or more affected sites.

7. The method of claim 5 , wherein the horse suffers from acute laminitis and wherein the nedocromil sodium is administered in a single dose.

8. The method of claim 5 , the method further comprising administering another intravenous dose of cromolyn sodium to the horse within about 3 to 4 days after administering a first dose.

9. The method of claim 1 , wherein the dose is between about 1 and 7 mg/kg of the horse's body weight.

10. The method of claim 5 , wherein the dose is between about 1 and 7 mg/kg of the horse's body weight.

11. The method of claim 1 , where the horse suffers from chronic laminitis and wherein the cromolyn sodium is administered at least once a week.

12. The method of claim 5 , where the horse suffers from chronic laminitis and wherein the nedocromil sodium is administered at least once a week.

13. The method of claim 1 wherein the dose is administered through an intravenous injection into the horse's one or more affected legs.

14. The method of claim 5 wherein the dose is administered through an intravenous injection into the horse's one or more affected legs.

15. The method of claim 13 wherein the intravenous injection is into a digital vein of the one or more affected legs.

16. The method of claim 14 wherein the intravenous injection is into a digital vein of the one or more affected legs.

Assignments (2)
CHANGE OF NAME Recorded Jul 31, 2015
From: WILLOWCROFT PHARM, LLC
To: WILLOWCROFT PHARM INC
Reel/Frame 036243/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2009
From: OWEN, CHARLES F.
To: WILLOWCROFT PHARM, LLC
Reel/Frame 023417/0376 →
Continuity (4)
Continuation In Part 12387166 · Apr 29, 2009
Continuation In Part 11047068 · Jan 31, 2005
Provisional Application 60598186 · Aug 2, 2004
Related Publication 20090304648A1 · Dec 10, 2009